1. How many patients were treated in the last 4 months (April to July 2024) by the dermatology department with each of the following products:
· Abrocitinib
· Acitretin
· Alitretinoin
· Azathioprine
· Baricitinib
· Ciclosporin
· Dupilumab
· Lebrikizumab
· Methotrexate
· Mycophenolate mofetil
· Pimecrolimus
· Phototherapy (UVB or PUVA) - for Atopic Dermatitis only
· Tacrolimus ointment
· Tralokinumab
· Upadacitinib
|
Drug
|
<18
|
>18
|
Additional
|
|
acitretin
|
<5
|
90
|
|
|
Alitretinoin
|
0
|
9
|
|
|
Pimecrolimus
|
7
|
19
|
|
|
Tacrolimus
|
16
|
59
|
|
|
Abrocitinib
|
0
|
0
|
|
|
Azathioprine
|
NA
|
NA
|
we are unable to delineate dermatology patients and so cannot provide an answer for this drug
|
|
Baricitinib
|
<5
|
0
|
|
|
Ciclosporin
|
NA
|
NA
|
we are unable to delineate dermatology patients and so cannot provide an answer for this drug
|
|
Dupilumab
|
179
|
0
|
|
|
Lebrikizumab
|
0
|
0
|
|
|
Methotrexate
|
NA
|
NA
|
we are unable to delineate dermatology patients and so cannot provide an answer for this drug
|
|
Mycophenolate
|
NA
|
NA
|
we are unable to delineate dermatology patients and so cannot provide an answer for this drug
|
|
Tralokinumab
|
13
|
0
|
|
|
Upadacitinib
|
7
|
0
|
|
2. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:
· Age 6-11
· Age 12-17
· Age 18 and above
Response incorporated into answers to question 1
